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Background: IL-1β is a pleiotropic pro-inflammatory cytokine and its up-regulation is closely associated with
various cancers including gastrointestinal tumors. However, it remains unclear how IL-1β may contribute to the
initiation and development of these inflammation-associated cancers. Here we investigated the role of IL-1β in
colon cancer stem cell (CSC) development.
Methods: Using self-renewal assay, soft-agar assay, invasion assay, real-time PCR analysis, immunoblot assay and
shRNA knockdown, we determined the effects of IL-1β on cancer stem cell development and
epithelial-mesenchymal transition (EMT) in human primary colon cancer cells and colon cancer cell line HCT-116.
Results: We found that IL-1β can increase sphere-forming capability of colon cancer cells in serum-free medium.
IL-1β-induced spheres displayed an up-regulation of stemness factor genes (Bmi1 and Nestin) and increased drug
resistance, hallmarks of CSCs. Importantly, expression of EMT activator Zeb1 was increased in IL-1β-induced spheres,
indicating that there might be a close association between EMT and IL-1β-induced CSC self-renewal. Indeed, IL-1β
treatment led to EMT of colon cancer cells with loss of E-cadherin, up-regulation of Zeb1, and gain of the
mesenchymal phenotype. Furthermore, shRNA-mediated knockdown of Zeb1 in HCT-116 cells reversed
IL-1β-induced EMT and stem cell formation.
Conclusion: Our findings indicate that IL-1β may promote colon tumor growth and invasion through activation of
CSC self-renewal and EMT, and Zeb1 plays a critical role in these two processes. Thus, IL-1β and Zeb1 might be
new therapeutic targets against colon cancer stem cells.
Keywords: Colon cancer, Tumor microenvironment, Inflammation, Interleukin-1β, Cancer stem cells, Epithelial-
mesenchymal transition, Zeb1Background
Chronic inflammation is a predisposing cause of various
cancers. Interestingly, inflammatory cells and mediators
are present in every tumor, including those that are not
developed from chronic inflammation [1,2]. The inflam-
matory microenvironment around the tumor is a critical
component that drives tumor progression, and it is often
characterized as the seventh hallmark of cancer [3].
Interleukin-1β (IL-1β) is an important mediator of cancer-
related inflammation and can be secreted by immune,
stromal and tumor cells [4]. IL-1β levels are increased in a
variety of cancers including colon cancer, one of the most
common fatal cancers [5,6]. Recent studies have shown* Correspondence: leiwang@vet.k-state.edu; jshi@vet.k-state.edu
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reproduction in any medium, provided the orthat the interaction between colon cancer cells and
immune cells induces secretion of IL-1β from immune
cells [7,8]. Elevated IL-1β levels have been associated with
increased colon tumor growth and invasion [9,10]. How-
ever, how IL-1β may contribute to the development of
cancer has not been fully explored.
Cancer stem cells (CSCs) are a subpopulation of tumor
cells with the ability to undergo self-renewal and recapitu-
late the entire tumor population in vitro and in vivo [11].
Similar to CSCs from other types of cancers, colon CSCs
have been identified from human colon tumor cells using
flow cytometry and measuring the expression of stem cell
markers [12-14]. The ability to form spheroid cultures in
serum-free conditions supplemented with growth factors is
also used for identification and expansion of CSCs in vitro
[12,15]. In addition to the capability of self-renewal, CSCshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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static growth that resemble the primary tumors, and are
resistant to conventional chemotherapy/radiotherapy, im-
plicating that they are responsible for tumor growth and
recurrence [16]. Recently, we and others have shown that
soluble factors within tumor microenvironment play
an important regulatory role in the self-renewal and
fate of CSCs [17,18]. We speculate that IL-1β may
promote tumor growth by increasing the self-renewal
capability of colon CSCs.
Epithelial-mesenchymal transition (EMT) is a process
which involves epithelial cells acquiring a mesenchymal
phenotype and migratory capability, and plays an important
role in tumor metastasis [19,20]. EMT can be triggered by
various extracellular stimuli and microenvironment factors.
The induction of EMT is mediated by a set of key tran-
scription factors within the cell, including Twist, Snail,
Snug, Zeb1 and Zeb2, many of which are frequently over-
expressed in cancer cells [20]. These EMT activators
directly repress the expression of E-cadherin, an integral
component of adherens junctions. Importantly, EMT
process has been associated with the acquisition of stem
cell properties in normal and cancer cells [21,22]. The link
between EMT and CSCs enables cancer cells to migrate
from the primary tumor and colonize distant sites.
In this study, we investigated whether IL-1β could pro-
mote stem cell and EMT phenotypes in human colon
HCT-116 cells as well as in newly established primary
colon cancer cells. HCT-116 cells are a well-characterized
cellular model of human colon cancer and have been
broadly used for colon cancer research. The low passages
of freshly isolated human colon cancer cells have allowed
us to closely mimic the in vivo state and generate more
physiologically relevant data. Here, we provide direct
evidence that IL-1β promotes self-renewal of colon cancer
cells as well as their acquisition of EMT phenotype,
and this induction of CSC and EMT phenotypes was
mediated by Zeb1.
Results
Characterization of human primary colon cancer cells
During the first week of culture, all cells freshly isolated
from normal mucosa failed to survive, and the majority
of cells isolated from colon tumor sections died as well,
leaving only a few remaining healthy cells. The initial
primary colon cancer cells grew slowly and the culture
was maintained for four weeks before they were split for
the first passage. Early passages (passage 1–3) of human
primary colon cancer (HPCC) cells were used in all
experiments in this study.
The morphology of HPCC cells was first examined
using a light phase-contrast microscope. During the first
few days after plating, HPCC cells proliferated and formed
polarized epithelial islets. While in advanced growth (afterseven days), HPCC cells grew as multilayers and formed
tumor-like cell clusters, similar to the morphology of
colon cancer cell line HCT-116 (Figure 1A). The HPCC
culture contained epithelial cells and did not have fibro-
blasts as determined by immunofluorescence staining with
anti-pan-cytokeratin (an epithelial cell marker) and anti-
vimentin (a fibroblast cell marker), in which cells
reacted only with anti-pan-cytokeratin and were
negative for anti-vimentin (Figure 1B).
To assess tumorigenic potential of HPCC cells, we
performed a colony-forming assay that is frequently
utilized for in vitro evaluation of malignant trans-
formation and tumorigenesis [23]. HPCC cells exhibited
transforming capability by forming colonies over the
period of two weeks (Figure 1C).
IL-1β promotes sphere formation, expression of stemness
markers, and drug resistance
To investigate whether IL-1β promotes self-renewal of
colon cancer cells, an important feature of CSCs, we pla-
ted HCT-116 and HPCC cells at very low densities in
96-well plates containing serum-free medium with or
without IL-1β. The newly formed spheres were then
measured and total number of cells was counted. HCT-
116 cells grew readily as spheres in serum-free medium.
The presence of IL-1β markedly increased the number
and size of spheres (Figure 2A & 2B, left panel), as well
as the total number of cells (Figure 2C, left panel), com-
pared to that of control HCT-116 cells. Unlike HCT-16
cells, most HPCC cells grew as a monolayer in serum-
free medium. However, addition of IL-1β to the medium
resulted in increased sphere formation (Figure 2A & 2B,
right panel) and cell proliferation (Figure 2C, right
panel). As sphere formation and growth represent the
ability of cell self-renewal, these data suggest that IL-1β
promotes self-renewal capacity in colon cancer cells, a
critical characteristic of CSCs.
To further characterize IL-1β-induced spheres and de-
termine the molecular mechanisms underlying these
observations, we evaluated the expression of several
stemness genes in HCT-116 and HPCC cells treated
with or without IL-1β in serum-free medium using real
time PCR (Figure 3A). We found that the expression of
Bmi1, nestin and Nanog were significantly up-regulated
in IL-1β-treated HCT-116 cells, compared to that in
control cells. Likewise, the expression of Bmi1 and Nestin
was increased in IL-1β-induced HPCC sphere cells as well
(Figure 3A). The enhanced expression of Bmi1 and nestin
in IL-1β-treated HCT-116 cells and HPCC cells was further
confirmed by immunoblotting (Figure 3B). These
results indicate that IL-1β-induced spheres contain
enriched population of CSCs.
Recent studies suggest that CSCs exhibit intrinsic
resistance to conventional chemotherapies [24]. Thus, we
Figure 1 Characterization of human primary colon cancer cells (HPCC). (A) HPCC cells exhibit epithelial-like morphology as human colon
cancer cell line HCT-116. During initial growth in culture (Upper panel), HPCC cells formed small islets; while in late stage of growth (lower panel)
they formed multilayer culture, similar to HCT-116 cells. Scale bar = 200 μm. (B) HPCC cells react only with cytokeratin but not vimentin as
determined using an immunofluoresent staining assay. Nuclei (blue staining) were counterstained with DAPI. Scale bar = 20 μm. (C) HPCC display
transformation capability as determined using a soft-agar assay. HPCC cells (1x104/well) were plated in soft agar containing the medium with
10% FBS in 6-well plates for 14 days. Scale bar = 50 μm.
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could display enhanced drug resistance against carbopla-
tin, a conventional chemotherapeutic agent. HCT-116
cells were cultured in serum-free medium with or without
IL-1β for five days and then exposed to various concentra-
tions of carboplatin for two days. Cell viability was mea-
sured as the percentage of live cells relative to total cell
number (dead + live cells). As shown in Figure 3C, IL-1β-
treated sphere cells displayed significantly greater
resistance to carboplatin at concentrations range from
250 to 1000 μM.
To assess whether IL-1β-induced formation of CSCs
was associated with EMT, we examined the expression
of EMT activators using real-time PCR and western blot
analyses. As shown in Figure 3D and 3E, Zeb1 expres-
sion (gene transcript and protein) were augmented in
IL-1β-induced HCT-116 and HPCC sphere cells in
serum free medium. Interestingly, although the magni-
tude of induction of Zeb1 mRNA by IL-1β in HPCC
cells was markedly greater than that in HCT-116 cells
(5.5 fold vs. 1.5 fold, Figure 3D), the difference in Zeb1protein induction by IL-1β was not that dramatic
between HPCC and HCT-116 cells (1.8 fold vs. 1.5 fold,
Figure 3E). Nonetheless, this result suggests that Zeb1
may be involved in IL-1β-mediated reactivation or de
novo induction of cancer stem cells.
IL-1β induces an EMT phenotype and enhances
invasiveness of colon cancer cells
Since Zeb1, a transcription factor that mediates EMT, was
up-regulated in IL-1β-induced stem cells in serum free
medium, we then investigated whether IL-1β could induce
EMT phenotype in colon cancer cells. HCT-116 and
HPCC cells were cultured in McCoy’s 5A Medium with
1% FBS in the presence or absence of 200 pM IL-1β for
seven days. In the absence of IL-1β, HCT-116 and HPCC
cells displayed an epithelial cell phenotype and formed
islets. In contrast, in the presence of IL-1β both groups of
cells acquired a more fibroblast-like, spindle-shaped
morphology indicative of mesenchymal cells (Figure 4A).
The morphological transformation was consistent with
reduction of E-cadherin expression in IL-1β-treated
Figure 2 IL-1β induces sphere formation and proliferation of colon cancer cells in serum-free medium (SFM). (A) Representative images
of HCT-116 and HPCC cells in the absence or presence of IL-1β. HCT-116 and HPCC cells (1 cell/μl) were cultured in 96-well plates containing
100 μl SFM in each well with or without IL-1β for seven days. The number of spheres was counted under a microscope and size was measured
using ImageJ (B and C). Then sphere cells were dissociated and stained with Trypan blue and counted under a microscope. Error bars represent
SEM. *p < 0.05.
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(Figure 4B & 4C). To identify the factors that
mediated IL-1β-induced EMT in colon cancer cells,
we examined the expression patterns of E-cadherin
transcriptional repressors using rt-PCR. It was found
that the expression of Zeb1 (Figure 4B), but not Snail or
Twist (data not shown), was up-regulated in HCT-116
cells and HPCC EMTcells.To determine whether IL-1β-induced EMT cells had
increased invasiveness as conferred by EMT, a wound
healing assay was used to assess cell migration. An
area devoid of cells was created at time 0 by scraping
a monolayer of HCT-116 cells and followed by incu-
bation of the cells with or without IL-β for 48 h.
Compared to control cells, IL-β-treated HCT-116 cells
showed a significantly (p < 0.05) higher rate of
Figure 3 IL-1β-induced sphere cells express stem cell markers and Zeb1. (A) Transcription levels of stem cell markers in control and IL-1β-
treated colon cancer cells. HCT-116 and HPCC cells were cultured in SFM with or without IL-1β for seven days. mRNA levels of stem cell markers
were determined by real-time PCR. β-actin was used as an internal normalization control. Error bars represent SEM. *p < 0.05. (B) Immunoblot
analysis for Bmi1 and Nestin from control and IL-1β-treated cells. β-actin was used as an sample loading control. (C) IL-1β-induced sphere cells
develop drug resistance. The control and IL-1β-induced sphere cells were treated with various concentrations of carboplatin for two days. Then,
cells were dissociated and stained with Trypan blue, and counted under a microscope. The viability was determined by the percentage of live
cells over the sum of live and dead cells. *p < 0.05, **p < 0.01. (D). Transcription levels of Zeb1 in control and IL-1β-treated colon cancer cells.
HCT-116 and HPCC cells were cultured in SFM with or without IL-1β for seven days. mRNA levels of Zeb1 were determined by real-time PCR. β-
actin was used as an internal normalization control. Error bars represent SEM. *p < 0.05. (E). Immunoblot analysis for Zeb1 from control and IL-1β-
treated cells. β-actin was used as an sample loading control. Normalized quantification of band intensities on immunoblots for Zeb1 is listed
under each band.
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along the scraped area had almost coalesced 48 h
after scraping (Figure 5A & 5B).The proliferation status of HCT-116 cells grown under
the same conditions was also assessed at the indicated
time after plating (Figure 5C). As shown in Figure 5C,
Figure 4 IL-1β induces EMT in colon cancer cells. (A) IL-1β induces morphological changes from epithelial-like to fibroblast-like appearances
in colon cancer cells. HCT-116 and HPCC cells were cultured in the medium with 1% FBS in the presence or absence of IL-β for seven days. Scale
bar = 200 μm. (B) Transcription levels of Zeb1 and E-cadherin as determined by real-time PCR. β-actin was used as an internal normalization
control. Error bars represent SEM. *p < 0.05. (C) Immunoblot analysis for E-cadherin from control and IL-1β-treated cells. β-actin was used as an
sample loading control.
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control cells between 0–36 h time point, but signifi-
cantly (p < 0.05) more rapidly than control cells after
36 h. This result indicates that enhanced proliferation
may have contributed to the faster wound closure of
IL-1β-treated culture at late stage, but not during the
early-to-mid stage of wound healing.
IL-1β-induced EMT in HCT-116 cells is mediated by Zeb1
To determine whether IL-1β-induced self-renewal and
EMT in HCT-116 cells were due to the up-regulation of
Zeb1, we sought to selectively suppress the expression of
Zeb1 using shRNA. HCT-116 cells were transduced with
lentiviral vectors carrying scrambled shRNA or specific
shRNAs against Zeb1. We first examined the impact of
Zeb1 knockdown on IL-1β-induced EMT. The twostable shRNA pools expressing scrambled and Zeb1
shRNAs (shZeb1) were cultured in MCCOY’S 5A
MEDIUM with 1% FBS in the presence or absence of
IL-1β for seven days. As shown in Figure 6A, HCT-116
cells treated with shZeb1 demonstrated a more epithelial
phenotype in the presence of IL-1β, which was simi-
lar to that displayed by HCT-116 cells in the absence
of IL-1β regardless whether they were treated with
shZeb1 or the scramble shRNA. In contrast, HCT-
116 cells treated with scramble shRNA displayed
spindle-shape morphology after IL-1β stimulation,
similar to that of control (without shRNA treatment)
HCT-116 cells after IL-1β stimulation (Figure 4A).
This observation is consistent with the notion that
Zeb1 might be responsible for IL-1β-induced EMT in
HCT-116 cells.
Figure 5 IL-1β enhances invasiveness and proliferation of colon cancer cells. (A) Representative images of wounds at 0 and 48 h in the
presence or absence of IL-1β. Confluent monolayers of HCT-116 cells were scraped by a pipette tip to generate wounds and then were cultured
in the presence or absence of IL-1β for 48 h. (B) Relative wound width represented as percentages compared to the wound width at 0 h. (C)
Proliferation of HCT-116 cells in the presence or absence of IL-1β as measured by cell count. Error bars represent SEM. *p < 0.05.
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in IL-1β-induced EMT in HCT-116 cells, we first measured
the expression of Zeb1 in HCT-116 cells treated with
scrambled shRNA or shZeb1. As shown in Figure 6B, Zeb1
protein expression in shZeb1-treated cells was reduced
compared to that in HCT-116 cells treated with scramble
shRNAs in the absence of IL-1β, and its expression was not
increased in the presence of IL-1β. In contrast, Zeb1
expression in HCT-116 cells treated with scrambled shRNA
was increased 2.7 fold after IL-1β treatment (Figure 6B, left
panel). This clearly indicates that the IL-1β-induced Zeb1
was knocked down effectively. Because the expression
of E-cadherin in shZeb1-treated cells did not change
in the presence or absence of IL-1β (Figure 6B), our
data support the notion that Zeb1 is indeed responsible for
IL-β-induced suppression of E-cadherin in HCT-116 cells.
IL-1β-induced CSC self-renewal in HCT-116 cells is
mediated by Zeb1 and Bmi-1
To determine whether Bmi-1 is involved in IL-1β-Zeb1-
mediated CSC development, we evaluated the effect ofZeb1 knockdown on IL-1β-induced Bmi1 expression
and self-renewal of HCT-116 cells. Cells were cultured
in serum-free medium in the presence or absence of
IL-1β for seven days and the expression of Zeb1 and Bmi1
were examined by immunoblotting. As expected, Zeb1
protein expression was enhanced in scramble cells after
IL-1β treatment, but was reduced in shZeb1 cells with or
without IL-1β, compared to scramble cells without IL-1β
treatment (Figure 7A). Similarly, Bmi1 expression in
shZeb1 cells was remarkably decreased compared to
scramble cells, and still remained at the low level
after IL-1β treatment. The parallel expression patterns
between Zeb1 and Bmi1 indicates that Zeb1 may
regulate the expression of Bmi1 in HCT-116 cells
treated with IL-1β.
To determine the effect of Zeb1 knockdown on self-
renewal of HCT-116 cells, scramble and shZeb1 cells
were cultured at a very low density (1 cell/μl) in 96-well
plates containing serum-free medium with or without
IL-1β for seven days. In the absence of IL-1β, Zeb1
knockdown cells showed reduced self-renewal capability
Figure 6 Knockdown of Zeb1 inhibits IL-1β-induced EMT in HCT-116 cells. (A) Zeb1 knockdown cells still maintain epithelial appearance
seven days after treatment with IL-1β. Scale bar = 200 μm. Scramble and shZeb1 HCT-116 cells were cultured in the medium with 1% FBS in the
presence or absence of IL-1β for seven days. (B) Zeb1 knockdown inhibits IL-β-induced suppression of E-cadherin expression. Immunoblot
analysis for Zeb1 and E-cadherin was performed on lysates from control and IL-1β-treated cells. β-actin was used as an sample loading control.
Normalized quantification of band intensities on immunoblot for Zeb1 and E-cadherin is listed under each band.
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compared to scramble cells (Figure 7B & 7C). The
reduced self-renewal capability of Zeb1 knockdown cells
is comparable to their reduced Bmi-1 expression
(Figure 7A). IL-1β treatment led to a significant increase
in the number and size of spheres formed from
scramble cells, paralleled with their increased Bmi1
expression. As for Zeb1 knockdown cells, IL-1β failed
to significantly increase the number of spheres, but
the size of these spheres was significantly (p < 0.05)
increased (Figure 7B & 7C). The limited effect of
Zeb1 knockdown on IL-1β-mediated sphere size in-
crease suggests that in addition to Zeb1, other factors
may also contribute to IL-1β-enhanced self-renewal
capability. However, the significant inhibition of Zeb1
knockdown on IL-1β-mediated increase of sphere
number suggests that Zeb1-Bmi1 pathway is indeed
involved in regulation of IL-1β-induced self-renewal.
Discussion
IL-1β is a pleiotropic cytokine with numerous roles in
various physiological and pathological states. Aberrant
production and signaling of IL-1β are tightly linked totumor generation, growth and metastasis in multiple
types of cancers [25-29]. Thus far, the exact mechanisms
by which IL-1β promotes tumor growth have remained
unclear. Using a colon cancer cell line HCT-116 and pri-
mary colon cancer cells, we have found that IL-1β can
promote sphere-forming capacity concomitant with up-
regulated expression of stemness markers Bmi1 and nes-
tin in colon cancer cells, suggesting that IL-1β increases
the self-renewal of colon CSCs. In addition, IL-1β-
induced spheres display augmented drug resistance, a
property associated with CSCs. Importantly, IL-1β
induces cellular morphological changes in colon cancer
cells that are consistent with the acquisition of EMT
phenotype as characterized by the loss of E-cadherin
expression. Furthermore, IL-1β-induced EMT cells
display enhanced migratory capacity compared with
parental cells with an epithelial phenotype. Overall,
our studies provide the first evidence that IL-β pro-
motes CSC self-renewal and EMT in colon cancer
cells, which may contribute to colon cancer growth,
metastasis and recurrence.
Bmi-1 is a transcriptional repressor belonging to the
polycomb group protein family, which functions in gene
Figure 7 Zeb1 knockdown decreases Bmi1 expression as well as sphere-forming capability in HCT-116 cells treated with or without
IL-1β. (A) Zeb1 knockdown inhibits Bmi1 expression in either IL-1β-treated or untreated cells. Scramble and shZeb1 HCT-116 cells were cultured
in SFM in the presence or absence of IL-1β for seven days. Expression of Zeb1 and Bmi1 was determined using immunoblot assay on lysates
from scramble and shZeb1 cells treated with or without IL-1β. β-actin was used as an sample loading control. Normalized quantification of band
intensities on immunoblot for Zeb1 and Bmi1 is listed under each band. (B) Zeb1 knockdown reduces sphere-forming capability in HCT-116 cells
as well as inhibits IL-1β-induced sphere formation. Scramble or shZeb1 cells (1 cell/μl) were cultured in 96-well plates containing 100 μl SFM in
each well with or without IL-1β for seven days. The number of spheres was counted under a microscope and size was measured using ImageJ.
The data are presented as relative sphere number and size as compared to scramble cells cultured in the absence of IL-1β. Error bars represent
SEM. *p < 0.05.
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plays a crucial role in the self-renewal of normal and
neoplastic stem cells [32-37]. In addition to Bmi-1, several
other molecules have been proposed as colon CSC
markers including CD133, CD44, Lgr-5 and pluripo-
tency genes such as Oct-4, Sox-2 and Nanog [38].
However, recent studies by others have shown that
NANK, a human colon tumor cell line with a high
level of Bmi-1 expression but negative for CD133,
CD44, Oct4, and Nanog, is capable of initiating
tumors in mice [39]. This report suggests that Bmi-1
is crucial for the self-renewal and oncogenic potential
of colon CSCs. In addition, aberrant expression of
Bmi-1 has been reported in human colon cancer and
its expression levels correlate with clinical and patho-
logical stages of colon malignancies, further assuring
the oncogenic role of Bmi-1 in colon cancer [40-42].
Here we have found that the enhanced sphere formation
and proliferation in HCT-116 and HPCC cells treated
with IL-1β are associated with significantly augmented
Bmi-1 expression in these cells. This observation supports
the notion that IL-1β acts through Bmi-1 to promote the
self-renewal and proliferation of colon cancer stem cells.Zeb1, Zeb2 and transcription factors such as Snail,
Slug, E47 and Twist are all able to activate EMT through
binding to the E-cadherin promoter and repressing its
transcription [43]. In this study, we found that the
expression of Zeb1, but not Zeb2, Snail or Twist, was
up-regulated in IL-1β-induced HCT-116 and HPCC
EMT cells. This indicates that IL-1β may act through
Zeb1 to induce EMT in colon cancer cells. The import-
ance of Zeb1 in IL-1β-induced EMT in colon cancer
cells is further highlighted in Zeb1 knockdown HCT-116
cells, which display a close association between the lack
of EMT and the disappearance of IL-1β-induced repres-
sion of E-cadherin transcription in these cells (Figure 6).
Interestingly, IL-1β-induced Zeb1 expression has also
been observed in head and neck squamous carcinoma
cells [44]. Thus, Zeb1 may play a key role in IL-1β-induced
EMT in various cancer cells.
It has been reported that Zeb1 links the EMT process
and acquisition of CSC properties through a double-
negative feedback loop with microRNA-200, a repressor
of Bmi1 expression [45-48]. Our results show that
Zeb1 was also up-regulated along with Bmi1 in IL-
1β-induced HCT-116 and HPCC spheres. Thus, the
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suggests that IL-β-induced self-renewal of colon
cancer cells may involve the Zeb1-Bmi1 pathway.
This notion is supported by the behavior of Zeb1
knockdown HCT-116 cells, in which Bmi1 expression is
reduced in the absence of IL-1β and its expression is not
increased in the presence of IL-1β, compared to that in
control cells (Figure 7A). In addition, Zeb1 knockdown
cells displayed reduced self-renewal capacity in the
absence or presence of IL-1β, compared to that of control
cells (Figure 7B).
Although our data support the hypothesis that Zeb1-
Bmi1 pathway is critical for IL-β-induced self-renewal of
colon CSCs, we cannot rule out the possibility that other
stemness factors are also involved in IL-β-induced self-
renewal. This is because Zeb1 knockdown cells still
demonstrate obvious increases in the self-renewal
capacity after IL-β treatment. Thus, we speculate that
IL-1β enhances self-renewal of colon CSCs through
activating a multifaceted stemness system in which the
Zeb1-Bmi1 pathway is a part of an essential network.
Conclusion
EMT enables tumor metastasis and CSC self-renewal is
a key driving force for tumor growth and recurrence
after chemotherapy. IL-1β is a major pro-inflammatory
cytokine that has been closely linked to enhanced growth
and invasion of colon cancer. Using a colon cancer cell
line and primary colon cancer cells, we have demonstrated
that IL-1β may act via Zeb1 to promote EMT and stem
cell development in colon cancer cells, which may
contribute to colon tumor malignancy. Thus, IL-1β
and Zeb1 can be potential therapeutic targets aimed
at cancer stem cells in the development of novel
treatments for colon cancer.
Methods
Isolation of primary colon cancer cells and cell culture
Tumor samples and corresponding normal mucosa from
a patient with stage 2 colon cancer were obtained from
the Surgical Associates, Manhattan, KS. The proposal
(#5753) to isolate human colon cancer cells was
reviewed and approved by the Institutional Review
Board (IRB) for Kansas State University. At operation,
collected tissues were placed in McCoy’s 5A Medium
with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin (Invitrogen Corp, Carlsbad, CA) on ice
and transported to the laboratory immediately. The fresh
tissue was cut into small pieces (1 mm) using scissors
and digested with 3 ml (0.4 mg/ml) Collagenase A
(Roche Applied Science, Indianapolis, IN) at 37°C for
1 h with interval agitation. Twenty microliter of EDTA
(500 mM) was used to stop the reaction. The dis-
persed tissues were quickly mixed in a homogenizerand the mixture was filtered through a 70 μm strainer
(BD Falcon, San Jose, CA) to remove tissue fragments.
Cells were washed with PBS, spun down by centrifugation
and cultured in McCoy’s 5A Medium with 10% FBS and
1% penicillin-streptomycin in a humidified incubator
with 37°C and 5% CO2.
Human colon cancer cell line HCT-116 was obtained
from the American Type Culture Collection (Manassas,
VA) and maintained in McCoy’s 5A Medium with 10%
FBS and 1% penicillin-streptomycin. To induce EMT,
HCT-116 cells and primary colon cancer cells HPCC
were cultured in McCoy’s 5A Medium with 1% FBS in
the presence 200 pM IL-1β (R&D Systems, Minneapolis,
MN) for seven days. To induce sphere formation, cells
were cultured in serum-free medium (SFM) which
consisted of neurobasal-A medium supplemented with
B27, GlutaMAX-I supplement, 1% penicillin-streptomycin
(all from Invitrogen Corp), 50 ng/ml heparin (Sigma-
Aldrich, Saint Louis, MO), 20 ng/ml of EGF, and 20 ng/ml
bFGF (R&D systems, Minneapolis, MN). To determine
the effect of IL-1β, 200 pM IL-1β was added to the
serum-free medium every other day.
Immunostaining
Primary colon cancer cells were seeded in slide cham-
bers (Fisher Scientific, Hanover Park, IL) and cultured
for seven days in McCoy’s 5A Medium with 10% FBS.
Then, cells were fixed with 4% paraformaldehyde, per-
meablized with PBS containing 0.5% Triton X-100, and
incubated with pan-cytokeratin (C 2562, Sigma) or
vimentin (sc-6260, Santa Cruz Biotechnology, Santa
Cruz, CA) mouse monoclonal antibodies, and followed
by secondary chicken anti-mouse IgG (H + L) antibody
conjugated with Alexa 488 (Invitrogen). Cells were then
mounted with VECTASHIELD Mounting Medium with
DAPI (Vector laboratories, Burlingame, CA) and observed
with a confocal microscope.
Soft agar colony formation assay
Anchorage independent growth in soft agar was used
to determine the transformation and growth of the
primary colon cancer cells in vitro. The soft agar
assay was performed in 6-well plates containing two
layers of Sea Plague Agar (Invitrogen). The bottom
layer consisted of 0.8% agar in 1 ml of McCoy’s 5A
Medium with 10% FBS. The primary colon cancer
cells (1x104/well) were placed in the top layer con-
taining 0.4% agar in the same medium as the bottom.
Cells were cultured for 14 days and colonies were
photographed under a microscope.
Chemoresistance assay
Control monolayer and IL-1β-induced sphere cells in
serum-free medium were treated with carboplatin
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for two days. Then cells were stained with Trypan
blue (Amresco Inc., Solon, OH) and counted under a
microscope. The viability of the cells was measured
as the percentage of live cells over the total of live
and dead cells.
Wound healing assay
HCT-116 cells were cultured for four days in 6-well
plates containing McCoy’s 5A Medium plus 10%
serum to generate a confluent monolayer. The media
was then removed and two wounds per well were
made by scraping with pipette tips. The wounds were
examined to ensure that the cells were removed
completely. The plates were washed twice with PBS
to remove cellular debris and then McCoy’s 5A
Medium with 1% serum with or without IL-1β was
added. Pictures from the same area of the wound
were taken under a microscope at 0, 12, 24 and 48 h
after scraping. For each wound, the distance of the
gap was the average of four fields. The measurement
for six wounds per treatment were collected and
analyzed statistically.
Self-renewal assay and cell proliferation assay
HCT-116 cells (1 cell/μl in SFM) and primary colon cancer
cells (1 cell/μl in SFM) were seeded at 100 μl/well in
96-well plates and treated with or without 200 pM
IL-1β for seven days. IL-1β was added every other
day. The total number of spheres in each well was
counted under a microscope. Then cells were disso-
ciated, stained with Trypan blue (Amresco Inc., Solon,
OH) and counted under a microscope to determine
the total cell number.
RNA extraction and real-time PCR
Total RNA was extracted using TRI reagent (Sigma-
Aldrich), followed by digestion with a DNase kit (Ap-
plied Biosystems, Carlsbad, California) to remove DNA
residues. Reverse transcription was carried out using the
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and
quantitative real-time PCR was performed using SsoFast
Eva Green Supermix kit (Bio-Rad). β-actin was used as
an internal normalization control.
Immunoblotting
HCT-116 cells and primary colon cancer cells were cul-
tured in McCoy’s 5A Medium with 1% FBS or in serum-
free medium in the absence or presence of IL-1β for
seven days. Cells were then washed with cold PBS, lysed
in RIPA buffer [25 mM Tris–HCl (pH 7.6), 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS)
and pelleted by centrifugation. Protein concentrations
were determined using a NanoDrop instrument (ThermoScientific, Wilmington, DE). Cell lysates (30 μg pro-
tein for each sample) were incubated for 5 min at
1000C in 2x loading buffer, separated by electrophor-
esis in 10% polyacrylamide gels, and transferred to
PVDF membranes (Millipore, Bedford, MA). Mem-
branes were blocked with 5% milk in TBST and then
incubated with primary antibodies. The anti-Zeb1,
anti-Nestin and anti-Bmi1 (H99) antibodies were from
Santa Cruz biotechnology (Santa Cruz, CA). The anti-
E-cadherin and anti-Bmi1 clone F6 antibodies were from
Millipore and anti-β-actin antibody was from Sigma. After
washing with TBST, the membrane was incubated with
one of the two secondary antibodies, HRP-conjugated
goat anti-mouse IgG-HRP (Millipore) or anti-rabbit IgG
HRP-linked antibody (Cell Signaling, Danvers, MA). De-
tection was performed using HyGLO substrate (Denville
Scientific, Metuchen, NJ) and images were taken using an
AlphaEaseFC imaging system (Cell biosciences, Santa
Clara, CA). The graph digitizing software UN-SCAN-IT
(Silk Scientific, Orem, Utah) was used to quantify
intensities of protein bands.
Infection with shRNA lentiviral particles
HCT-116 cells were cultured in McCoy’s 5A Medium
with 10% FBS until they became 50% confluent. Then
cells were infected with scrambled or Zeb1 shRNA lenti-
viral particles (Santa Cruz) as described by the manufac-
turer. Stable infected cells were established via selection
with puromycin (10 μg/ml).
Statistical analysis
Student’s t test was used to determine statistical signifi-
cance for all analyzed data. We consider a two-sided
p < 0.05 as significant.
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